Matthew Kucmanic, MA, MPH and Amy R. Sheon, PhD, MPH
Using focus groups to obtain stakeholder feedback can lead to epistemic injustices if the decision-making process is not perceived as procedurally fair.
AMA J Ethics. 2017;19(11):1073-1080. doi:
10.1001/journalofethics.2017.19.11.ecas1-1711.
Parents’ false beliefs can be engaged respectfully to motivate deliberations about shared values and goals, but refusal of clinically indicated treatment could warrant reporting.
AMA J Ethics. 2018;20(11):E1017-1024. doi:
10.1001/amajethics.2018.1017.
Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward.
AMA J Ethics. 2019;21(5):E394-400. doi:
10.1001/amajethics.2019.394.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.